Chiasma Reports First Quarter 2017 Results WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

Chiasma Reviews 2015 Accomplishments and Outlines Core Objectives for 2016 Ended 2015 with Between $148 Million and $149 Million in Cash, Cash Equivalents and Marketable Securities, Which the Company Believes is Sufficient to Fund Operations at Least Through Mid-2017 ...